相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer
Taichi Miyawaki et al.
SUPPORTIVE CARE IN CANCER (2022)
Low skeletal muscle mass predicts frailty in elderly head and neck cancer patients
C. D. A. Meerkerk et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2022)
A Retrospective Analysis of a Cohort of Patients Treated With Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer
Michel Bila et al.
FRONTIERS IN ONCOLOGY (2022)
The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab
Juliette H. R. J. Degens et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2021)
Patterns, Predictors, and Prognostic Value of Skeletal Muscle Mass Loss in Patients with Locally Advanced Head and Neck Cancer Undergoing Cisplatin-Based Chemoradiotherapy
Najiba Chargi et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
Lorena Arribas et al.
FRONTIERS IN ONCOLOGY (2021)
An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives
Daniel Lenouvel et al.
ORAL DISEASES (2020)
Disease-induced and treatment-induced alterations in body composition in locally advanced head and neck squamous cell carcinoma
Anna C. H. Willemsen et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2020)
Adiposity May Predict Survival in Patients With Advanced Stage Cancer Treated With Immunotherapy in Phase 1 Clinical Trials
Dylan J. Martini et al.
CANCER (2020)
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study
Alessio Cortellini et al.
SCIENTIFIC REPORTS (2020)
Skeletal Muscle Mass Change During Chemotherapy: A Systematic Review and Meta-analysis
Min Kyeong Jang et al.
ANTICANCER RESEARCH (2020)
Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score
Yushi Ueki et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2020)
Management of Cancer Cachexia: ASCO Guideline
Eric J. Roeland et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapy
Maria Van Rijn-Dekker et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Impact of CT-based body composition parameters at baseline, their early changes and response in metastatic cancer patients treated with immune checkpoint inhibitors
Amandine Crombe et al.
EUROPEAN JOURNAL OF RADIOLOGY (2020)
Inflammation and Skeletal Muscle Wasting During Cachexia
Justine M. Webster et al.
FRONTIERS IN PHYSIOLOGY (2020)
Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer
Panagiota Economopoulou et al.
CANCERS (2020)
The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer
J. H. R. J. Degens et al.
LUNG CANCER (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Neutrophil-to-lymphocyte ratio as a prognostic indicator in head and neck cancer: A systematic review and meta-analysis
Tristan Tham et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2018)
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris et al.
ORAL ONCOLOGY (2018)
Chemotherapy-induced muscle wasting: association with NF-κB and cancer cachexia
Jeffrey S. Damrauer et al.
EUROPEAN JOURNAL OF TRANSLATIONAL MYOLOGY (2018)
A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors A Meta-analysis of Correlation and Differences in Effect Sizes
Bishal Gyawali et al.
JAMA NETWORK OPEN (2018)
Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer
Susanne Blauwhoff-Buskermolen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Interplay between the immune system and adipose tissue in obesity
Mark A. Exley et al.
JOURNAL OF ENDOCRINOLOGY (2014)
Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index
Lisa Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Definition and classification of cancer cachexia: an international consensus
Kenneth Fearon et al.
LANCET ONCOLOGY (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
Erik von Elm et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)
分享论文
